Form 4: Gilead Sciences CEO Reports Stock Transaction
Insider Transaction (Form 4)
Daniel Patrick O'Day, Chairman & CEO and a Director of Gilead Sciences, Inc., reported multiple transactions in common stock on September 10, 2026.
Summary
- Option exercise/conversion: acquired 8,780 Common Stock on September 10, 2026; holds 585,913 after (Direct).
- Tax/exercise-price withholding: disposed of 4,230 Common Stock at $144.81 ($612,546) on September 10, 2026; holds 581,683 after (Direct).
- Option exercise/conversion: disposed of 8,780 Restricted Stock Unit on September 10, 2026; holds 83,300 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Daniel Patrick O'Day — Director, Officer (Chairman & CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Option exercise/conversion | Common Stock | 8,780 | — | — | 585,913 |
| 2026-09-10 | Tax/exercise-price withholding | Common Stock | 4,230 | $145 | $612.5K | 581,683 |
| 2026-09-10 | Option exercise/conversion | Restricted Stock Unit | 8,780 | — | — | 83,300 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Option exercise/conversion (8,780 shares) |
| 2026-09-10 | Tax/exercise-price withholding (4,230 shares) |
| 2026-09-10 | Option exercise/conversion (8,780 shares) |
Keywords
insider transaction, Form 4, GILD, GILEAD SCIENCES, INC., neutral, Daniel Patrick O'Day
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.